Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us


Global Influenza Medication Market: Looming Patent Expires Likely to Stymie Growth

Press release Description

Albany, New York, March 21, 2018: A new exhaustive study titled “Influenza Medication Market – Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 – 2025” has recently been submitted to the database of Market Research Reports Search Engine (MRRSE). According to the report, the global influenza medication market is likely to grow at a sluggish CAGR of 1.4% during the assessment period, and surpass US$ 2 Bn in revenues by the end of the forecast period.

According to the report, increase in the prevalence of influenza cases around the world is one of the key factors driving the growth of the market. Regions that have a higher prevalence of flu are witnessing a higher demand for influenza medication. Governments in many countries is promoting the use of influenza medication to control the outbreak of epidemics. These factors are likely to provide an impetus to the growth of the market during the assessment period.

Although effective influenza treatment is likely to remain a key driver for market growth, patent expires are one of the key reasons for the sluggish growth in the market. Long clinical approval procedures can stymie the growth of the market during the assessment period.

The report segments the global influenza medication market into distribution channel, product and region. The distribution channel segment has further sub-segmented the global market into pharmacies, clinics, hospitals and others. The product segment is categorized into inosine, rimantadine, amantadine, peramivir, oseltamivir, zanamivir and other (laninamivir octanoate, etc.). Geographically, the market is divided into key regions globally which are North America, Latin America, Europe, Asia Pacific, Middle East & Africa.

Asia Pacific is one of the leading markets for influenza medication globally, on account of high prevalence for the disease in these developing countries. The demand for influenza medication in these countries is likely to remain steady during the assessment period, and provide significant growth opportunities for manufacturers. In addition to Asia Pacific, demand is also likely to be resurgent in North America and Europe. While US is likely to be the leading market in North America, demand for influenza medication is higher in western Europe.

The report profiles some of the leading players operating in the market. Some of the major players profiled are F. Hoffmann-La Roche Ltd., Sandoz International GmbH (Novartis AG), Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. GlaxoSmithKline plc, Mylan, Inc., Natco Pharma and Daiichi Sankyo Company. These players are focusing on developing an effective pipeline of drugs and gaining regulatory approval quickly.

Browse Full Global  Influenza Medication Market Report with TOC :

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords. 

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.


State Tower
90, State Street
Suite 700
Albany, NY – 12207
United States

Telephone: +1-518-730-0559